A pilot study for evaluation of the efficacy and safety of telmisartan in reducing microalbuminuria in hypertensive patients with type 2 diabetes mellitus

Journal of the Indian Medical Association

Volumn 103, Issue 3, 2005, Pages 187-191

  Kulkarni, R B ^a,b   Kulkarni, B N ^a,c   Hariharan, R S ^a,d   Naikwadi, Akram ^a,e   Gawde, Ashish ^a   Baliga, Vidyagauri ^a,f   Desai, Anish ^a  

^a Glenmark Pharmaceuticals Limited   (India)

^b Government Medical College Hospital   (India)

^c Government General Hospital   (India)

^d MADRAS MEDICAL COLLEGE   (India)

^e KBN College of Engineering   (India)

^f Medical Services

Author keywords

Angiotensin receptor blockers (ARBs); Angiotensin converting enzyme (ACE); End stage renal disease; Hypertension; Microalbuminuria; Nephropathy; Telmisartan; Type 2 diabetes mellitus

Indexed keywords

ALBUMIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; TELMISARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE;

ADULT; ADVERSE DRUG REACTION; AGE; ANGINA PECTORIS; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DISEASE CONTROL; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INDIA; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT MONITORING; PHYSICAL EXAMINATION; SYSTOLIC BLOOD PRESSURE; TITRIMETRY; TREATMENT OUTCOME; URINARY EXCRETION; AGED; ALBUMINURIA; ANALYSIS OF VARIANCE; DIABETIC NEPHROPATHY; INFANT; MIDDLE AGED; PILOT STUDY; PROSPECTIVE STUDY; SAFETY; SINGLE BLIND PROCEDURE;

ADULT; AGED; ALBUMINURIA; ANALYSIS OF VARIANCE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BENZOATES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; HYPERTENSION; INFANT; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; SAFETY; SINGLE-BLIND METHOD;

EID: 26944477863     PISSN: 00195847     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Wild S, Roglic G, Greene A, Sicree R, King H - Global prevalence of diabetes- estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-53.
2. Zandbergen AA, Baggen MG, Lamberts SW - Effect of losartan on microalbuminuria in normotensive patients with type 2 diabetes mellitus- a randomized clinical trial. Ann Intern Med 2003; 139: 90-6.
3. Krolewski AS, Laffel LM, Krolewski M, Quinn M, Warram JH - Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med 1995; 332: 1251-5.
4. Bennett PH, Haffner S, Kasiske BL, Keane WF, Mogensen GE, Parving HH, et al - Screening and management of microalbuminuria in patients with diabetes mellitus. Recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the Council on Diabetes Mellitus of the National Kidney Foundation. Am J Kidney Dis 1995; 25: 107-12.
5. Tobe SW, Naimark UM, McFarlane PA - Microalbuminuria in diabetes mellitus. Can Med Assoc J 2002; 167: 499-503.
6. American Diabetic Association Position Statement - Diabetic nephropathy. Diabetes Care 2003; 26: S94-8.
7. Hilgers KF, Mann JF - ACE inhibitors versus AT1 receptor antagonists in patients with chronic renal disease. J Am Soc Nephrol 2002; 13: 1100-8
8. Lewis EJ, Hunsicker LG, Clarke WR, Bert T, Pohl MA, Lewis JB. et al, Collaborative Study Group - Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60.
9. Brenner BM, Cooper ME, DeZeeuw D, Keane WF, Mitch WE, Parving HH, et al, RENAAL Study Investigators - Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9.
10. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Amer P - Ibersartan in patients with type 2 diabetes and Microalbuminuria Study Group: the effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-8.
11. Sharpe M, Jarvis B, Goa KL - Telmisartan: a review of its use in hypertension. Drugs 2001; 61: 1501-29.
12. Lacourciere Y, Nadeau A, Poirier L, Tancrede G - Captopril or conventional therapy in hypertensive type II diabetics: three year analysis. Hypertension 1993; 21: 786-94.
13. UK Prospective Diabetes Study Group -Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-20.
14. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M - Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118: 577-81.
15. Estacio RO, Jeffers BW, Gifford N, Schrier RW - Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000, 23: B54-64.
16. Parving HH, Andersen S, Jacobsen P, Christensen PK, Rossing K, Hovind P, et al - Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points. Semin Nephrol 2004; 24: 147-57.
17. Price DA, De Oliveira JM, Fisher ND, Hollenberg NK - Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy men. Hypertension 1997; 30: 240-6.
18. Price DA, Porter LE, Gordon M, Fischer ND, De'Oliveira JM, Laffel LM, et al - The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol 1999; 10: 2382-91.
19. Osei, SY, Price DA, Laffel LMB, Lansang MC, Hollenberg NK - Effect of angiotensin II antagonist eprosartan on hyperglycemia-induced activation of intrarenal renin-angiotensin system in healthy humans. Hypertension 2000; 36: 122-6.
20. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervett J, et al - Diabetics exposed to telmisartan and enalapril study group. Angiotensin - receptor blockade versus converting enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351: 952-61.
21. Bakris GL - The evolution of treatment guidelines for diabetic nephropathy: strategies integrate JNC VI, more recent protocols. Postgrad Med 2003; 113: 35-50.